Skip to main content

Percutaneous Coronary Intervention News

Racial, Ethnic, Economic Disparities Identified in Adoption of PCI Services

TUESDAY, July 9, 2024 – Hospitals serving communities with large proportions of Black and Hispanic residents and with residential segregation are less likely to adopt percutaneous coronary...

Radial Access for Percutaneous Coronary Intervention Now Dominant Method

THURSDAY, May 16, 2024 – Use of radial access for percutaneous coronary intervention (PCI) increased 2.8-fold in the United States between 2013 and 2022, according to a study presented at the annual...

FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention

June 22, 2015 – The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries,...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Plavix, clopidogrel